Advertisement

Tumor Biology

, Volume 37, Issue 11, pp 15079–15085 | Cite as

Low expression of DCXR protein indicates a poor prognosis for hepatocellular carcinoma patients

  • Xiaofeng Hang
  • Zhiqin Wu
  • Kaijian Chu
  • Guanzhen Yu
  • Haoran Peng
  • Haiguang Xin
  • Xiaohui Miao
  • Junxue Wang
  • Wensheng Xu
Original Article
  • 227 Downloads

Abstract

The aim of this study was to investigate the prognostic value of dicarbonyl/L-xylulose reductase (DCXR) in human hepatocellular carcinoma (HCC). Immunohistochemistry and tissue microarrays were used to evaluate DCXR protein expression levels. Image-Pro Plus was used to calculate the integral optic density (IOD) in each tissue sample, which represented the expression level of DCXR. DCXR proteins were found to be significantly lower in HCC tumor tissues (P < 0.0001) according to immunohistochemical analysis of DCXR protein levels in 74 paired HCC tissue and peritumoral non-cancer tissues. The prognostic value of DCXR in HCC was assessed in 290 cases of the training cohort and 74 cases of the validation cohort. Shorter overall survival (OS) time and shorter time to recurrence (TTR) in both the training and validation set were found to be associated with lower expression levels of DCXR. In the training set, the expression level of DCXR in HCC was an independent prognostic factor for OS according to univariate and multivariate analyses. In conclusion, DCXR expression is an independent prognostic factor for OS and TTR of post-operative HCC patients, and low expression levels of DCXR in HCC may indicate poor outcome of HCC patients after surgical resection.

Keywords

Dicarbonyl/L-xylulose reductase Hepatocellular carcinoma Prognosis Tissue microarray 

Notes

Acknowledgments

This study was supported by the National Science and Technology Major Project of China (No. 2012ZX10002007-001-005), and National Natural Science Foundation of China (Grant Nos. 81371829 and 31500141).

Compliance with ethical standards

All procedures were approved by the Human Research Ethics Committee at the Eastern Hepatobiliary Surgery Hospital and ChangZheng Hospital, and written informed consent was obtained from all patients before obtaining the tumor samples.

Conflicts of interest

None.

References

  1. 1.
    Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–17.CrossRefPubMedGoogle Scholar
  2. 2.
    Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277–300.CrossRefPubMedGoogle Scholar
  3. 3.
    YF X, Yi Y, Qiu SJ, Gao Q, Li YW, Dai CX, et al. PEBP1 downregulation is associated to poor prognosis in HCC related to hepatitis B infection. J Hepatol. 2010;53:872–9.CrossRefGoogle Scholar
  4. 4.
    Waller LP, Deshpande V, Pyrsopoulos N. Hepatocellular carcinoma: a comprehensive review. World J Hepatol. 2015;7:2648–63.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Bellissimo F, Pinzone MR, Cacopardo B, Nunnari G. Diagnostic and therapeutic management of hepatocellular carcinoma. World J Gastroenterol. 2015;21:12003–21.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Nakagawa J, Ishikura S, Asami J, Isaji T, Usami N, Hara A, et al. Molecular characterization of mammalian dicarbonyl/L-xylulose reductase and its localization in kidney. J Biol Chem. 2002;277:17883–91.CrossRefPubMedGoogle Scholar
  7. 7.
    Cho-Vega JH, Tsavachidis S, Do KA, Nakagawa J, Medeiros LJ, McDonnell TJ. Dicarbonyl/L-xylulose reductase: a potential biomarker identified by laser-capture microdissection-micro serial analysis of gene expression of human prostate adenocarcinoma. Cancer Epidemiol Biomark Prev. 2007;16:2615–22.CrossRefGoogle Scholar
  8. 8.
    Liu Y, Wang X, Li S, Hu H, Zhang D, Hu P, et al. The role of von Willebrand factor as a biomarker of tumor development in hepatitis B virus-associated human hepatocellular carcinoma: a quantitative proteomic based study. J Proteome. 2014;106:99–112.CrossRefGoogle Scholar
  9. 9.
    Jin GZ, WL Y, Dong H, Zhou WP, YJ G, Yu H, et al. SUOX is a promising diagnostic and prognostic biomarker for hepatocellular carcinoma. J Hepatol. 2013;59:510–7.CrossRefPubMedGoogle Scholar
  10. 10.
    Szkandera J, Winder T, Stotz M, Weissmueller M, Langsenlehner T, Pichler M, et al. A common gene variant in PLS3 predicts colon cancer recurrence in women. Tumour Biol. 2013;34:2183–8.CrossRefPubMedGoogle Scholar
  11. 11.
    Tan N, Liu Q, Liu X, Gong Z, Zeng Y, Pan G, et al. Low expression of B-cell-associated protein 31 in human primary hepatocellular carcinoma correlates with poor prognosis. Histopathology. 2016;68:221–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10:7252–9.CrossRefPubMedGoogle Scholar
  13. 13.
    Hwang HW, Ha SY, Bang H, Park CK. ATAD2 as a poor prognostic marker for hepatocellular carcinoma after curative resection. Cancer Res Treat. 2015;47:853–61.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Seo SI, Kim HS, Kim WJ, Shin WG, Kim DJ, Kim KH, et al. Diagnostic value of PIVKA-II and alpha-fetoprotein in hepatitis B virus-associated hepatocellular carcinoma. World J Gastroenterol. 2015;21:3928–35.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Shen Q, Fan J, Yang XR, Tan Y, Zhao W, Xu Y, et al. Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study. Lancet Oncol. 2012;13:817–26.CrossRefPubMedGoogle Scholar
  16. 16.
    San Miguel C, Fundora Y, Triguero J, Muffak K, Villegas T, Becerra A, et al. Immunosuppression strategies in the treatment of hepatocellular carcinoma in Virgen de las Nieves university hospital. Transplant Proc. 2015;47:2371–3.CrossRefPubMedGoogle Scholar
  17. 17.
    Yang XR, Xu Y, Yu B, Zhou J, Li JC, Qiu SJ, et al. CD24 is a novel predictor for poor prognosis of hepatocellular carcinoma after surgery. Clin Cancer Res. 2009;15:5518–27.CrossRefPubMedGoogle Scholar
  18. 18.
    El-Kabbani O, Ishikura S, Darmanin C, Carbone V, Chung RP, Usami N, et al. Crystal structure of human L-xylulose reductase holoenzyme: probing the role of Asn107 with site-directed mutagenesis. Proteins. 2004;55:724–32.CrossRefPubMedGoogle Scholar
  19. 19.
    Matsunaga T, Kamiya T, Sumi D, Kumagai Y, Kalyanaraman B, Hara A. L-xylulose reductase is involved in 9,10-phenanthrenequinone-induced apoptosis in human T lymphoma cells. Free Radic Biol Med. 2008;44:1191–202.CrossRefPubMedGoogle Scholar
  20. 20.
    Tanaka M, Katayama F, Kato H, Tanaka H, Wang J, Qiao YL, et al. Hepatitis B and C virus infection and hepatocellular carcinoma in China: a review of epidemiology and control measures. J Epidemiol. 2011;21:401–16.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Niu J, Lin Y, Guo Z, Niu M, Su C. The epidemiological investigation on the risk factors of hepatocellular carcinoma: a case-control study in Southeast China. Medicine (Baltimore). 2016;95:e2758.CrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2016

Authors and Affiliations

  • Xiaofeng Hang
    • 1
  • Zhiqin Wu
    • 1
  • Kaijian Chu
    • 2
  • Guanzhen Yu
    • 3
  • Haoran Peng
    • 4
  • Haiguang Xin
    • 1
  • Xiaohui Miao
    • 1
  • Junxue Wang
    • 1
  • Wensheng Xu
    • 1
  1. 1.Department of Infection Diseases, Changzheng HospitalSecond Military Medical UniversityShanghaiPeople’s Republic of China
  2. 2.Department VI of Hepatic Surgery, Eastern Hepatobiliary Surgery HospitalSecond Military Medical UniversityShanghaiPeople’s Republic of China
  3. 3.Department of Oncology, Changzheng HospitalSecond Military Medical UniversityShanghaiPeople’s Republic of China
  4. 4.Department of MicrobiologySecond Military Medical UniversityShanghaiPeople’s Republic of China

Personalised recommendations